Kurs
+31,49%
Kurs
+31,49%
Open
1,37
High
1,65
Low
1,37
Close
1,62
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
16,9 MNOK
Likviditet
16,9 MNOK
Rel. mcap
1,71%
Antal aktier
10 849 282
Likviditet under dagen för detta pressmeddelande
Kalender
Tid* | ||
2025-04-24 | - | Årsstämma |
2025-02-26 | 07:00 | Bokslutskommuniké 2024 |
2024-08-30 | - | Kvartalsrapport 2024-Q2 |
2024-04-12 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2024-04-11 | - | Årsstämma |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-08-31 | - | Kvartalsrapport 2023-Q2 |
2023-04-27 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2023-04-26 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-08-31 | - | Kvartalsrapport 2022-Q2 |
2022-04-29 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2022-04-28 | - | Årsstämma |
2022-03-01 | - | Bokslutskommuniké 2021 |
2021-11-18 | - | 15-10 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-26 | - | Kvartalsrapport 2021-Q1 |
2021-04-28 | - | Årsstämma |
2021-04-16 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2021-03-22 | - | Extra Bolagsstämma 2021 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-19 | - | Kvartalsrapport 2020-Q3 |
2020-10-21 | - | Extra Bolagsstämma 2020 |
2020-08-27 | - | Kvartalsrapport 2020-Q2 |
2020-06-11 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2020-06-10 | - | Årsstämma |
2020-05-26 | - | Kvartalsrapport 2020-Q1 |
2020-02-27 | - | Bokslutskommuniké 2019 |
2019-11-19 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-23 | - | Kvartalsrapport 2019-Q1 |
2019-04-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2019-04-25 | - | Årsstämma |
2019-02-18 | - | Extra Bolagsstämma 2019 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-31 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2018-05-30 | - | Årsstämma |
2018-05-30 | - | Kvartalsrapport 2018-Q1 |
2018-02-27 | - | Bokslutskommuniké 2017 |
2017-12-20 | - | Extra Bolagsstämma 2017 |
2017-11-22 | - | Kvartalsrapport 2017-Q3 |
2017-08-23 | - | Kvartalsrapport 2017-Q2 |
2017-05-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2017-05-24 | - | Årsstämma |
2017-05-24 | - | Kvartalsrapport 2017-Q1 |
2017-02-28 | - | Bokslutskommuniké 2016 |
2016-11-23 | - | Kvartalsrapport 2016-Q3 |
2016-10-12 | - | Extra Bolagsstämma 2016 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
2016-05-31 | - | Kapitalmarknadsdag 2016 |
2016-05-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2016-05-19 | - | Årsstämma |
2016-05-19 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | Bokslutskommuniké 2015 |
2015-11-17 | - | Kapitalmarknadsdag 2015 |
2015-10-21 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2015-05-27 | - | Kvartalsrapport 2015-Q1 |
2015-03-09 | - | Årsstämma |
2014-11-12 | - | Extra Bolagsstämma 2014 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2023-11-15 08:30:03
15.11.2023 08:30:01 CET | Thor Medical ASA | Non-regulatory press releases
Oslo, 15 November 2023: Thor Medical ASA has signed Letters of Intent (LOI) with
three radiopharmaceutical companies for future supply of alpha emitters.
The LOI's signed to date are with radiopharmaceutical companies developing novel
cancer therapies, one US-based and two Scandinavian companies. All companies
have advanced to clinical trials for their products.
Given the successful outcome of the clinical trials, which will bring the drugs
to market, the estimated future demand for alpha emitters from these potential
customers exceeds the initial planned production capacity of Thor Medical's
first industrial-scale manufacturing facility.
"The partnership with these companies demonstrates the market maturity in this
industry and for our products and supports bringing alpha emitters to market at
scale quickly. We will target to develop the agreements into concrete delivery
contracts as part of the work to make a final investment decision for our first
industrial-scale manufacturing facility in 2025", says Alf Bjørseth, CEO of Thor
Medical ASA.
Thor Medical will continue to develop relationships with other potential
customers of alpha emitters in the radiopharmaceutical industry going forward.
CONTACTS
* Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.no
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visitwww.thormedical.no - https://www.thormedical.no.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/2749/3850/Download%20announcement
%20as%20PDF.pdf